APOE
EmergingAPOE ε4 is the strongest common genetic risk factor for Alzheimer's disease and now informs anti-amyloid therapy safety monitoring.
APOE comes in different genetic versions, and one of them (ε4) is the strongest common genetic risk factor for Alzheimer's disease. This is now checked before starting newer Alzheimer's drugs, since carriers face a higher risk of a specific drug side effect.
Apolipoprotein E (APOE) is a lipid-transport protein with three common genetic variants (ε2, ε3, ε4); it plays roles in both lipid metabolism and, separately, neurodegenerative disease risk.
The APOE ε4 allele is the strongest common genetic risk factor for late-onset Alzheimer's disease, with homozygous ε4/ε4 carriers facing substantially higher lifetime risk; APOE genotype is also relevant to certain cancer contexts and to cognitive effects following cancer therapy.
Measured via genetic testing (genotyping), not a standard blood level assay; APOE ε4 status is increasingly assessed before starting anti-amyloid Alzheimer's therapies (lecanemab, donanemab), since ε4 carriers face higher risk of ARIA (amyloid-related imaging abnormalities), a treatment-related brain swelling/microhemorrhage side effect.
APOE ε4 genotype informs risk counseling and monitoring intensity (more frequent MRI surveillance) for patients starting anti-amyloid antibody therapy, given the elevated ARIA risk in carriers.
Genotyping before anti-amyloid antibody treatment helps identify patients at higher risk of ARIA (a treatment side effect).
- General neurology and genetics reference literature on APOE ε4 in Alzheimer's disease risk and anti-amyloid therapy safety monitoring.